Oxford Nanopore signs CRISPR licence

UK-based Oxford N anopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

INTA 2026: In-house tips on what to do in London

21 April 2026 With the start of the first-ever INTA Annual Meeting held in the UK capital just weeks away, in-house IP counsel share their favourite ways to spend downtime in the city.

Europe

IP finance gap risks startup exodus, EUIPO warns

13 April 2026 New report finds that just 13% of IP-owning firms have sought financing through their assets, with billions in potential funding left untapped, as structural barriers persist.

Europe

Patent office fee increases: What applicants must know

13 April 2026 Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.

More features

Litigator from Brown Rudnick moves firms to chair practice

INTA 2026: In-house tips on what to do in London

Penile implant maker’s $17m trade secret award unravels

Appeals court eases Teva’s headache with reversal

Simmons & Simmons makes senior Asia trademark hire

Baker McKenzie strengthens IP bench with new German lead

Cancer drug researcher hit with suit over mutation-targeting tools

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Oxford Nanopore signs CRISPR licence

More on this story

Editor's picks

Editor's picks

More features